Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
Garlic Powder doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality meta-analyses and randomised trials published 1986–2021 with a typical study size of 60 participants.
Based on 18 studies · 1 meta-analysis · 17 RCTs · 1,285 total participants
Study base
18 studies indexed
By outcome
Every outcome below: Too few graded studies.
Cholesterol & lipids12 studies
12 studies
Heart & blood pressure5 studies
5 studies
Glucose & metabolic2 studies
2 studies
Weight management2 studies
2 studies
Liver health2 studies
2 studies
Inflammation1 study
1 study
Slowing down
Only 1 study in the last 5 years · Latest meta-analysis: 1994
198620032021
1RCTCited 127×n=50 · small study1998
In plain English: Garlic powder (900 mg/d) treatment for 12 weeks was ineffective in lowering cholesterol levels in patients with hypercholesterolemia.
Isaacsohn JL et al. · Archives of internal medicine (1998)
The active treatment arm received tablets containing 300 mg of garlic powder (Kwai) 3 times per day, given with meals (total, 900 mg/d).
There were no significant lipid or lipoprotein changes in either the placebo- or garlic-treated groups and no significant difference between changes in the placebo-treated group compared with changes in the garlic-treated patients.
In plain English: None of the variables showed significant differences between the garlic-treated and the placebo groups.
van Doorn MB et al. · The American journal of clinical nutrition (2006)
The subjects were randomly assigned to 3 parallel treatment groups: garlic powder (2.1 g/d), atorvastatin (40 mg/d), or placebo.
We conclude that a chemically well-characterized garlic preparation has no significant effect on inflammatory biomarkers, endothelial function, or lipid profile in normolipidemic subjects with risk factors for CVD.
In plain English: There were no significant differences between the groups receiving garlic and placebo in the mean concentrations of serum lipids, lipoproteins or apo A1 or B, by analysis either on intention-to-treat or treatment received.
Neil HA et al. · Journal of the Royal College of Physicians of London (1996)
The active treatment group received dried garlic tablets (standardised to 1.3% allicin) at a dosage of 300 mg three times daily.
In this trial, garlic was less effective in reducing total cholesterol than suggested by previous meta-analyses.
4RCTCited 55×n=75 · small study2004
In plain English: No significant differences between the garlic and placebo groups were detected for any of the outcome measures.
Turner B et al. · The British journal of nutrition (2004)
Seventy-five healthy, normo-lipidaemic volunteers (men and women aged 40-60 years) were assigned to dried garlic powder tablets (10.8 mg alliin (3-(2-propenylsulfinyl)-L-alanine)/d, corresponding to about three garlic cloves) or placebo.
Sixty-two subjects were eligible for the per-protocol analysis.
In plain English: The results suggest that this garlic powder preparation may be of some clinical use in subjects with mild hypertension.
Silagy CA et al. · Journal of hypertension (1994)
Eight trials were identified (all using the same dried garlic powder preparation (Kwai) with data from 415 subjects included in the analyses.
Only three of the trials were specifically conducted in hypertensive subjects, and many had other methodological shortcomings.
However, there is still insufficient evidence to recommend it as a routine clinical therapy for the treatment of hypertensive subjects.
6CrossoverCited 97×n=28 · very small study1995
In plain English: Comparing the period on garlic with that on placebo, there were no significant differences in plasma cholesterol, LDL cholesterol, HDL cholesterol, plasma triglycerides, lipoprotein(a) concentrations, or blood pressure.
Simons LA et al. · Atherosclerosis (1995)
After a baseline dietary period of 28 days, subjects took Kwai garlic powder tablets 300 mg three times daily or matching placebo for 12 weeks, followed by 28 days washout, followed by a 12 weeks crossover on the alternative preparation.
This study found no demonstrable effect of garlic ingestion on lipids and lipoproteins.
In plain English: At the end of the study, hepatic steatosis was significantly reduced in the treatment group compared with the control group (P = 0·001).
Sangouni AA et al. · The British journal of nutrition (2020)
Ninety NAFLD patients were randomly assigned to take either a garlic powder supplement or a placebo for 12 weeks.
The treatment group received four tablets of garlic daily (each tablet contained 400 mg garlic powder).
In addition, a significant decrease was seen in the serum concentration of alanine transaminase (P < 0·001), aspartate transaminase (P = 0·002), γ-glutamyltransferase (P = 0·003) as well as total cholesterol (P = 0·009), TAG (P < 0·001), HDL-cholesterol (P < 0·001) and LDL-cholesterol (P = 0·01) in the treatment group compared with the control group.
In plain English: For all subjects, LDL pattern A and B subjects combined, garlic treatment for three months resulted in no significant change in total cholesterol, LDL cholesterol, HDL cholesterol, HDL subclass distribution, postprandial triglycerides, apolipoprotein B, lipoprotein (a) (Lp[a]), LDL peak particle diameter or LDL subclass distribution.
Superko HR et al. · Journal of the American College of Cardiology (2000)
Following a two-month stabilization period, subjects were randomly assigned to a placebo or 300 mg three times a day of a standardized garlic tablet for three months.
In plain English: Allicor treatment (600 mg daily) resulted in a reduction of both systolic and diastolic blood pressures by 7.0 mm Hg (95% confidence interval (95% CI): 5.3-8.7) and 3.8 mm Hg (95% CI: 2.7-4.8), respectively.
Sobenin IA et al. · Hypertension research : official journal of the Japanese Society of Hypertension (2009)
After an 8-week placebo treatment run-in phase, patients were randomized either to 600 mg Allicor (n=30) or to placebo (n=20) daily for 8 weeks.
Increasing the Allicor dosage to 2400 mg daily did not provide any additional benefit.
Treatment with Kwai resulted in the same decrease in systolic blood pressure (5.4 mm Hg, 95% CI: 1.9-8.8) as that seen with Allicor, but no decrease in diastolic blood pressure was observed with Kwai.
In plain English: Garlic supplementation compared with the placebo led to a significant increase in high density lipoprotein-cholesterol (4.5 vs. -1.8, p < .001) and a significant reduction in waist circumference (-1.3 vs. 0.0, p = .001), diastolic blood pressure (-6.7 vs. 0.0, p < .001), systolic blood pressure (-7.7 vs. 0.5, p < .001)
Sangouni AA et al. · Phytotherapy research : PTR (2021)
Ninety subjects were assigned to receive 1,600 mg/d garlic powder or placebo for 3 months.
In plain English: By the end of the study, total cholesterol in Allicor-treated patients had fallen by 7.6% (p=0.004) as compared to the level at randomization, and was 11.5% lower than the placebo group (p=0.005).
Sobenin IA et al. · Journal of atherosclerosis and thrombosis (2008)
The lipid-lowering effects of time-released garlic powder tablets, Allicor (600 mg daily), were investigated in a double-blinded placebo-controlled randomized study in 42 men aged 35-70 with mild hypercholesterolemia.
HDL cholesterol also increased significantly after 8 and 12 weeks of treatment.
In plain English: After 3 months of treatment, mean CIMT difference from baseline was significantly differ between the two groups (p < 0.001).
Mahdavi-Roshan M et al. · Nutrition and health (2013)
The patients were randomly divided into two groups: garlic group (n = 27), receiving garlic powder tablet (1200 µg allicin/tab) twice daily and the placebo group (n = 29), receiving placebo for 3 months.
Plasma lipids and lipoproteins (total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, Apolipoprotein A1 and Apolipoprotein B) did not differ between the two groups.
In plain English: The difference between the verum and placebo group was highly significant (p less than 0.001).
Mader FH · Arzneimittel-Forschung (1990)
Patients were randomly allocated to take tablets containing a total of 800 mg garlic powder (standardized to 1.3% of alliin content) daily or the same number of placebo tablets for 16 weeks (monthly controlled).
221 patients were used for statistical analysis of total cholesterol and 219 patients for the analysis of triglyceride values.
14RCTCited 47×n=46 · small study2001
In plain English: After 12 weeks, the garlic supplement group (n=22) had a significant reduction in total cholesterol (TC, -0.36 mmol/L. -4.2%) and LDL-cholesterol (LDL-C, -0.44 mmol/L, -6.6%) while the placebo group (n=24) had a non-significant increase in TC (0.13 mmol/L, 2.0%) and LDL-C (0.18 mmol/L, 3.7%).
Kannar D et al. · Journal of the American College of Nutrition (2001)
Each subject was given dietary counseling to lower fat intake and enteric-coated Australian garlic powder tablets with 9.6 mg allicin-releasing potential or matching placebo tablets.
HDL-cholesterol was significantly increased in the placebo group (0.09 mmol/L, 9.1%), compared to the garlic group (-0.02 mmol/L, -0.9%).
In plain English: The results indicated that neither dosage of dried garlic showed any significant effect on any of the parameters measured.
Luley C et al. · Arzneimittel-Forschung (1986)
The doses administered were 3 X 198 mg in Study I (34 patients) and 3 X 450 mg in Study II (51 patients).
Both studies comprised placebo and therapy periods of 6 weeks each.
16RCTCited 60×n=51 · small study2010
Sobenin IA et al. · Lipids in health and disease (2010)
A small trial assessed lipids and calculated ten-year cardiovascular risk, not observed reductions in heart attacks or death.
The double-blinded placebo-controlled randomized study has been performed in 51 coronary heart disease (CHD) patients to estimate the effects of time-released garlic powder tablets Allicor on the values of 10-year prognostic risk of acute myocardial infarction (fatal and non-fatal) and sudden death, with the respect of secondary CHD prevention.
The main effect that played a role in cardiovascular risk reduction was the decrease in LDL cholesterol by 32.9 mg/dl in men (p < 0.05), and by 27.3 mg/dl in women.
In plain English: It has been demonstrated that treatment with Allicor resulted in better metabolic control due to the lowering of fasting blood glucose, serum fructosamine and serum triglyceride levels.
Sobenin IA et al. · Acta diabetologica (2008)
The metabolic action of Allicor was investigated in the 4-week double-blinded placebo-controlled study in 60 type 2 diabetic patients.
In plain English: Platelet aggregation induced by adenosine diphosphate and collagen, and especially beta-thromboglobulin (beta-TG) release after collagen stimulation were significantly inhibited 2 and 4 h after garlic ingestion; platelet aggregation values were also significantly lower after 7 and 14 days of garlic treatment.
Legnani C et al. · Arzneimittel-Forschung (1993)
The acute and chronic effects of a preparation of dried garlic powder (Sapec) in a total daily dose of 900 mg on fibrinolysis and platelet aggregation have been evaluated in a randomized, double-blind, placebo controlled cross-over study of 12 healthy subjects.
After 14 days of treatment, t-PA activity was significantly higher after garlic, with inter-treatment significance.